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perspective are c5,325 (±9588), c18,045c (±34487) and c41,716 (±35211) at mild, 
moderate and severe stages respectively in France; c3,125 (±4319), c8,457 (±18374) 
and c5,069 (±11747) in Italy. Associated EQ-5D utilities are respectively 0.79 (±0.18), 
0.39 (±0.37), −0.11 (±0.3) in France; 0.59 (±0.44), 0.39 (±0.42), 0.25 (±0.44) in Italy. 
The primary cost driver is productivity loss. In France, hospitalization and nursing 
home costs are the main components of direct costs. For more severely affected patients, 
medical resource utilization diminishes while caregiver involvement increases signiﬁ -
cantly (the shift is greater in Italy than France). Physical, mental and social HRQoL 
domains are all seriously affected. CONCLUSIONS: Euro-HDB is the ﬁ rst study to 
comprehensively assess the cost and HRQOL burden of HD. The 1:5 cost ratio 
(Italy : France) is consistent across most of the cost items, suggesting that differences in 
health care systems, access to health care and cultural attitudes towards caring for 
patients at home have a large impact on a country’s overall costs. Results suggest that 
HD has greater impact on HRQOL than Parkinson’s disease and Alzheimer’s disease.
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The economic burden of Multiple Sclerosis (MS) on society and the individuals con-
cerned is not known. Documenting such costs is essential for several reasons: costs of 
illness is a key factor of optimal disease management policies, knowledge of cost is 
useful for allocating research and development. The aim of our study as the ﬁ rst 
pharmacoeconomic investigation in Iran was to estimate the costs of multiple sclerosis 
according to severity of disease. Total, direct and indirect costs were compared in 160 
patients divided into three groups categorized by disease severity: stage I Expanded 
Disability Status Scale (EDSS < 2.5), stage II (EDSS 3–4.5) and stage III (EDSS > 5). 
The majority of these patients (94%) developed relapsing- remitting MS. a minority 
of the patients (0.2–4%) developed secondary progressive and primary progressive 
MS. Cost evaluation was performed from the societal perspective and covered the 
one-year period. The study was carried out at the Division of Neurology at Ghaem 
Hospital and MS association in Mashhad in northeast of Iran and was approved by 
the local ethics committee. The mean total cost/patient for one year was estimated at 
$27,095, $27,997and $31,662 for stage I, II and III, respectively. Both direct and 
indirect costs increased with MS progression. For indirect cost the main item was 
productivity loss. The mean extra medicine (treatments for MS symptoms and adverse 
effects of medications) cost/patient for one year was calculated at $19,036. This study 
conﬁ rms that MS represents a high economic burden to patients and society, with 
direct costs greatly exceeding indirect costs. As costs increase with disease progression, 
treatment efforts should focus on patients in the early stages of MS. Disease support 
system that monitors a variety of common progressive signs for the MS individuals is 
a key element of a management program as well.
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OBJECTIVES: According to EU-guidelines testing all patients on interferon-beta 
(IFNb) for presence of neutralizing antibodies (NAB) is recommended irrespective of 
clinical course and stop IFNb or switch to alternatives in patients who developed 
persistent NAB; based on the fact that development in persistently NAB-positive 
patients equals that of placebo-treated patients. Economic impact of NAB-testing in 
MS-patients has not been explored yet. METHODS: This analysis estimated the 
economic impact of NAB-testing versus not testing during IFNb treatment in MS-
patients (n = 3590) on Austria’s health care system. a cost of illness model (decision 
tree combined with an integrated Markov model, time horizon 5 years), based on the 
cohort of IFNb-treated patients was performed. Two alternatives were compared: 
Cost-effectiveness of NAB-testing versus no NAB-testing. The NAB-testing arm 
allowed switching to alternative therapies whereas no-NAB-testing did not. Direct 
costs comprised all treatment-costs of symptoms due to MS. Indirect costs were not 
included. All costs represent data from 2010 (discounted at 5%p.a). Clinical data and 
resource use were determined by literature/experts. Efﬁ cacy assessment was based on 
the outcome measure “relapses avoided.” RESULTS: Total discounted costs for all 
Austrian MS-patients on IFNb-therapy (incl. testing) from a health care system’s 
perspective amount to c187,764,180 for 5 years. Total costs for all MS-patients 
without testing amount to c176,331,610. The difference of costs between tested 
patients, and therefore switching, and not tested patients values c11,432,570. Con-
sidering all IFNb-treated patients and a time horizon of 5 years 1400 relapses can be 
avoided. Testing for NAB leads to costs per relapse avoided of c24,383p.a. versus 
c27,569p.a. when no tests are done resulting in a difference of c3,186 per patient in 
favour of NAB-testing. CONCLUSIONS: General NAB-testing in MS-patients on 
IFNb-therapy is reasonable and cost-effective. Patients switching to effective and more 
expensive alternatives do not account for higher health care costs. Furthermore, less 
relapses increase QoL.
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OBJECTIVES: Restless legs syndrome (RLS) affects 2 to 15% of the US population. 
Limited data exist on patient characteristics and charges associated with emergency 
department (ED) visits among patients with RLS. METHODS: Data from the 2007 
Healthcare Cost and Utilization Project’s Nationwide Emergency Department Sample 
were used. Patients were selected for inclusion if they had a diagnosis of RLS (ICD-
9-CM code 333.94). Study measures included patient demographics and charges 
associated with the ED visit. Study measures were reported separately for patients 
with a primary versus secondary RLS diagnosis. Among patients with a secondary 
RLS diagnosis, the most common primary diagnoses were reported. RESULTS: A total 
of 6133 patients with a primary RLS diagnosis and 140,931 patients with a secondary 
RLS diagnosis were identiﬁ ed. Common primary diagnoses among patients with a 
secondary RLS diagnosis included respiratory symptoms (7.0%), general symptoms 
(4.6%), and pneumonia (3.7%). Mean (Std. Err.) age was 54.5 (0.6) years among 
patients with a primary diagnosis and 64.0 (0.3) years among patients with a second-
ary diagnosis. In both cohorts, over two-thirds of patients were female, the most 
common geographic regions were the South and Midwest, and Medicare was the most 
common primary payer (41.0% of patients with a primary diagnosis and 59.3% of 
patients with a secondary diagnosis). Over 90% of patients with a primary diagnosis 
had a routine discharge compared to only 26.6% of patients with a secondary diag-
nosis, and most patients with a secondary diagnosis were admitted to the facility as 
an inpatient. Mean (Std. Err.) charges were $816 ($48) for patients with a primary 
diagnosis and $2,043 ($62) for patients with a secondary diagnosis. CONCLUSIONS: 
This nationally representative study suggests that patients admitted to the ED with 
RLS accrue substantial costs during their visit. Further research is needed to more fully 
assess the total economic burden of the disease.
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OBJECTIVES: A reimbursement policy issued by the Federal Joint Committee in 
Germany to reassess the beneﬁ t of cholinesterase inhibitors every six months in order 
to receive continued coverage by the Statutory Health Insurance triggered an addi-
tional need to periodically assess the cost-beneﬁ t of galantamine in the treatment of 
mild-to-moderate Alzheimer’s disease (AD). An economic model speciﬁ cally designed 
for the purposes of such an assessment was developed using the most up-to-date 
IQWiG guidelines for cost-beneﬁ t assessment. METHODS: The model uses a discrete 
event simulation to predict the course of AD through changes in cognition, behavioral 
disturbance, and function over time, and compare the costs and beneﬁ ts of galan-
tamine versus no-drug treatment and ginkgo biloba. Clinical data were mainly derived 
from analyses of pooled data from clinical trials. Epidemiological and cost data were 
obtained from literature and public data sources. Costs (2009 c) from the perspective 
of the German Statutory Health Insurance were used. Both costs and beneﬁ ts were 
discounted at 5%. Sensitivity analyses were performed to assess the robustness of the 
model outcomes. RESULTS: Over a 10-year period, galantamine on average delays 
time to severe stage of the disease by 3.57 and 3.36 months, compared to no-drug 
treatment and ginkgo biloba, respectively. Galantamine also reduces time spent insti-
tutionalized by 2.34 and 2.21 months, compared to no-drug treatment and ginkgo 
biloba, respectively. The use of galantamine is projected to yield net savings of c3,978 
and c3,972 per patient compared to respective treatments. CONCLUSIONS: Our 
analyses suggest that compared to no-drug treatment and ginkgo biloba, treatment 
with galantamine not only improves clinical beneﬁ ts, but also achieves savings in 
health care costs associated with care for patients with mild-to-moderate AD in 
Germany.
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OBJECTIVES: To evaluate in the French setting the cost-effectiveness of memantine 
as adjunct therapy to Cholinesterase inhibitors (ChEI) compared to ChEI monother-
apy in Alzheimer’s disease (AD) patients. METHODS: A cost-effectiveness analysis 
employed a 3-state Markov model (“non-institutionalized,” “institutionalized” and 
“dead”) and compared the treatment alternatives in terms of time to nursing home 
admission, Quality Adjusted Life-years (QALYs), and costs over a 7-year time horizon. 
Annual transition probabilities between states were derived from two observational 
cohort studies: Lopez et al 2009 (US) for institutionalization probabilities and Helmer 
et al 2001 (FR) for death probabilities. Costs were valued from health care system 
and societal perspectives, and included cost of AD medications (French National 
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Health Insurance database, 2009), costs of care in community and in institution 
(French National Assembly on AD management, report 2005). Results were reported 
in EUR 2009. Health-related utilities were obtained from preceding published eco-
nomic evaluations in AD (Getsios et al 2001). Costs and QALYs were discounted at 
annual rates of 0% (base-case analysis), 3% and 5%. Deterministic and probabilistic 
sensitivity analyses were carried out to test the robustness of model assumptions. 
RESULTS: Over the seven-year time horizon, patients treated with ChEI monotherapy 
spent on average 41.6 months before institutionalization. Overall costs were c72,469 
(health care system perspective) or c89,735 (societal perspective). QALYs were esti-
mated at 2.36. Memantine as adjunct therapy to ChEI was associated with a longer 
time to nursing home of 8.9 months, QALYs gains of 0.19 and a cost saving of c5900 
(health care system perspective) or c2200 (societal perspective), i.e. a dominant treat-
ment scenario versus ChEI monotherapy. CONCLUSIONS: This economic evaluation 
suggest that, from both a health care system and a societal perspective, memantine as 
adjunct therapy to ChEI is a cost-effective strategy in the management of AD patients 
compared with ChEI monotherapy.
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OBJECTIVES: Methylprednisolone sodium succinate (MP) is an acute therapeutic 
option for traumatic spinal cord injury (SCI). a pivotal multicentre randomized control 
trial reported modest functional improvements and increased clinical complications 
associated with an extended dose regimen of MP for 48 hours (48h-MP) versus a 
limited dose regimen of MP for 24 hours (24h-MP), resulting in clinical ambiguity 
between 48h-MP and 24h-MP. Concerning the health care burden imposed by this 
devastating form of neurotrauma, an economic assessment comparing the beneﬁ ts 
either MP regimen imparts has never been reported. We performed a cost-effectiveness 
analysis (CEA) of 48h-MP compared with 24h-MP to determine their impact on direct 
health care costs for this patient population. METHODS: A decision tree model, 
incorporating motor improvement and complication frequencies reported by the Third 
National Acute Spinal Cord Injury Study and utility scores (QALYs) obtained from 
an Australian cohort, measured outcomes and effects at 6 and 12 months post-injury. 
Survival data, direct health care expenditures and complication costs associated with 
SCI and MP intervention were obtained from published epidemiological and survey 
data. CEA was performed from the health care payer’s perspective, discounted at a 
rate of 4% annually with a lifetime horizon. Distributions of the incremental cost-
effectiveness ratio between the interventions were determined by Monte Carlo simula-
tion. The model was validated with sensitivity analyses by varying costs and outcome 
comparators. RESULTS: As a result, 48h-MP dominates 24h-MP, providing higher 
QALYs at lower costs. The lower costs associated with 48h-MP intervention was 
$35,703 per patient lifecycle. Earlier motor improvement maintained at 1-year post-
injury was a key variable favouring 48h-MP intervention, despite complications asso-
ciated with this dosing regimen. CONCLUSIONS: To conclude, 48h-MP is the 
cost-effective intervention for SCI in comparison to 24h-MP, wherein the former 
results in modestly improved motor function, an effect which is maintained up to at 
least 1-year post-injury.
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OBJECTIVES: To conduct a German economic evaluation of natalizumab compared 
to other disease modifying drugs (DMD) in relapsing-remitting Multiple Sclerosis (MS) 
from a societal perspective. METHODS: A Markov model was designed to compare 
costs and outcomes of Natalizumab (Nb), other DMD (interferon-beta, glatiramer 
acetate) and best supportive care (BSC). The expanded disability status scale (EDSS) 
and the line of treatment were used to deﬁ ne the distinctive Markov States. Transition 
probabilities for progression, treatment switches and withdrawals were derived from 
clinical studies and literature. German real-life treatment data of MS-patients under 
DMD were collected retrospectively (N = 554) and used to validate assumptions and 
conduct sensitivity analyses. Cost data and quality of life estimates were taken from 
a European burden of MS study. a time horizon of 30 years and annual discount rates 
of 3% for costs and outcomes were chosen. RESULTS: Treatment with Nb resulted 
in 8.13 avoided relapses over 30 years, and in 2.36 avoided relapses under other DMD. 
After 30 years, the proportion of surviving patients at a low state of disease (incl. 
EDSS 4) was 59% for the Nb group, 31% for the other DMD and 8% for patients 
in the BSC group. The average MS related costs over 30 years were estimated at 
c847,160 for Nb, c816,139 for other DMD, and c627,701 for BSC. Cost per quality 
adjusted life-year (QALY) was c60,938 for Nb, c64,481 for other DMD and c53,911 
for BSC. The incremental cost-effectiveness of Nb compared to other DMD was 
c24,919 per QALY. CONCLUSIONS: MS is a resource intense disease due to its 
chronic course and its severe impact on patients’ daily life. Long term analysis suggests 
that even treatment without DMD is expensive and leads to considerable inferior 
clinical outcomes. Treatment with DMD improves the situation of patients, with 
Natalizumab showing the highest efﬁ cacy and best cost-effectiveness ratio.
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OBJECTIVES: Parkinson’s Disease (PD) is both a chronic and progressive neurode-
generative disorder. a 24-hour prolonged release tablet (PR) of the dopamine agonist 
ropinirole was introduced next to three daily doses of ropinirole immediate release 
(IR). a randomized controlled trial (PREPARED) was conducted, comparing ropini-
role-IR with ropinirole-PR. Ropinirole-PR signiﬁ cantly improved the off-time and this 
analysis assesses the costs-effectiveness of the ropinirole-PR in PD patients who are 
not adequately controlled on L-dopa compated to ropinirole-IR. METHODS: A 
Markov-health-state-transition model was used with health states combining off-time 
≤25% and >25% per day, Hoehn & Yahr stages 2–5 and problematic dyskinesias. 
Time horizons are 5 years and lifelong. Costs and effects were discounted by 4% and 
1,5% respectively. Healthcare perspective was taken, covering direct costs related to 
medication, consults, nursing and patient care including informal care, based on an 
ongoing Dutch observational study in PD (IMPACT study). Clinical outcomes from 
the PREPARED-trial are extrapolated based on literature assumptions. Results are 
presented as incremental costs and QALY’s gained. Both univariate and probabilistic 
sensitivity analyses (PSA) were performed. RESULTS: Ropinirole-PR was associated 
with lower L-dopa use, less off-time and less problematic dyskinesias. This resulted 
in incremental QALY gains of 0.125 and 0.336 over respectively 5 years and lifetime. 
The health care costs per H&Y-stage increased with disease severity and amounted 
c916, c1,492, c11,295 and c11.295 for stage 2 to 5 over 6 months. Treatment with 
ropinirole-PR was more costly than ropinirole-IR with a difference of c7.266 over 5 
years and c17.773 over lifetime. Treatment with ropinirole-PR however reduced 
medical costs by c8,059 over 5 years and c69,532 over lifetime compared with rop-
inirol-IR, mainly due to reduced dyskinesia occurrence. Sensitivity analysis conﬁ rmed 
the robustness of the model. CONCLUSIONS: Patient-functioning and quality of life 
were improved with ropinirole-PR realizing cost-savings to the health care budget as 
compared to treatment with ropinirole-IR.
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BACKGROUND: Parkinson’s Disease (PD) is a central nervous system disorder 
caused by progressive deterioration of brain areas that produce dopamine. Oral 
dopaminergic therapies control the symptoms of the disease, but these require three 
or more times daily doses, so it is associated with poor compliance or adherence, 
which affects the overall efﬁ cacy and costs in health. OBJECTIVES: To analyze the 
cost-effectiveness of rotigotine versus pramipexole in patients with PD in Mexico. 
METHODS: We conducted an economic evaluation. The alternatives to compare were 
rotigotine 4, 6, 8 and 12  mg administered once daily versus pramipexole 3 mg/d and 
another scenario versus pramipexole 4.5 mg/d. The perspective is the Mexican Social 
Security Institute. The model included the cost of drug acquisition and management 
of adverse events (AE) for a 22 weeks period. The measure of efﬁ cacy was compliance 
or adherence to treatment, as a direct comparison study of rotigotine versus prami-
pexole demonstrated non-inferiority between the two alternatives. RESULTS: The 
compliance rate for rotigotine was 81% vs. 61% pramipexole. The costs were 
US$748, US$920, US$1113 and US$1701 for rotigotine 4, 6, 8 and 12 mg/d respec-
tively, compared with US$670 and US$967 for pramipexole 3 and 4.5 mg/d. The cost 
per successfully treated patient was lower for rotigotine 4, 6 and 8 mg/d (US$923, 
US$1 136 and US$1374, respectively) than with pramipexole 4.5 mg/d (US$1585). 
Rotigotine 4, 6, 8 and 12 mg/d were found to be a highly cost-effective strategy 
compared with pramipexole 3 and 4.5 mg/d, according to WHO criteria. CONCLU-
SIONS: The results of this analysis suggest that the use of rotigotine in patients with 
PD, represents a highly cost-effective strategy or cost saving for the public health 
institutions in Mexico. Rotigotine is an innovative alternative for easy administration 
(transdermal).
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OBJECTIVES: This study aimed to compare the cost-effectiveness (CE) of Bridion® 
(sugammadex) with neostigmine and spontaneous recovery (SR) approach in the 
reversal of neuromuscular blockade (NMB) induced by rocuronium/vecuronium, 
during anesthesia. METHODS: CE analysis (CEA) was performed by solving back 
the decision tree that included pathways starting with residual NMB and followed by 
hypoxia and pulmonary complications deﬁ ned as “aspiration, atelectasis and/or pneu-
monia” in patients, in whom NMB was induced by rocuronium/vecuronium. Bridion 
was compared with neostigmine and SR approach. Primary analysis parameters that 
